Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis

Seminars in Nephrology

Volumn 35, Issue 5, 2015, Pages 509-520

  Furie, Richard ^a,b   Toder, Kiley ^a   Zapantis, Ekaterini ^a  

^a Northwell Health   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Biologics; Clinical trials; Lupus nephritis; Small molecules; Treatment

Indexed keywords

ABATACEPT; ABETIMUS; ATACICEPT; AUTOANTIBODY; AUTOANTIGEN; BELIMUMAB; BG 9588; BIOLOGICAL MARKER; BORTEZOMIB; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; INFLIXIMAB; IXAZOMIB; LAQUINIMOD; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; OCRELIZUMAB; RITUXIMAB; SIRUKUMAB; TACROLIMUS; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; BORON DERIVATIVE; GLYCINE; HYBRID PROTEIN; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; OLIGONUCLEOTIDE; QUINOLONE DERIVATIVE; TACI RECEPTOR-IGG FC FRAGMENT FUSION PROTEIN;

ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; DRUG DEVELOPMENT; LUPUS NEPHRITIS; OFF LABEL DRUG USE;

ABATACEPT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; BORON COMPOUNDS; BORTEZOMIB; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GLYCINE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; ISOXAZOLES; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; OFF-LABEL USE; OLIGONUCLEOTIDES; QUINOLONES; RECOMBINANT FUSION PROTEINS; RITUXIMAB; TACROLIMUS; TREATMENT OUTCOME;

EID: 84961575876     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.08.012     Document Type: Review

References (44)

1. Furie R.A., Cash J.M., Cronin M.E., Katz R.S., Weisman M.H., Aranow C., et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001, 28:257-265.
2. Alarcon-Segovia D., Tumlin J.A., Furie R.A., McKay J.D., Cardiel M.H., Strand V., et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003, 48:442-454.
3. Cardiel M.H., Tumlin J.A., Furie R.A., Wallace D.J., Joh T., Linnik M.D., et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008, 58:2470-2480.
4. Linnik M.D., Hu J.Z., Heilbrunn K.R., Strand V., Hurley F.L., Joh T., et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:1129-1137.
5. Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000, 343:1156-1162.
6. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
7. Dooley M.A., Jayne D., Ginzler E.M., Isenberg D., Olsen N.J., Wofsy D., et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011, 365:1886-1895.
8. Mok C.C., Tong K.H., To C.H., Siu Y.P., Au T.C. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005, 68:813-817.
9. Liu Z., Zhang H., Liu Z., Xing C., Fu P., Ni Z., et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015, 162:18-26.
10. Wang H.Y., Cui T.G., Hou F.F., Ni Z.H., Chen X.M., Lu F.M., et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008, 17:638-644. China Leflunomide Lupus Nephritis Study Group.
11. Jayne D., Chan T.M., Barkay H., Weiss R., Wofsy D. A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care. Ann Rheum Dis 2013, 72:164.
12. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
13. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226.
14. Genovese M.C., Kaine J.L., Lowenstein M.B., Del Giudice J., Baldassare A., Schechtman J., et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008, 58:2652-2661.
15. Mysler E.F., Spindler A.J., Guzman R., Bijl M., Jayne D., Furie R.A., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013, 65:2368-2379.
16. Emery P., Rigby W., Tak P.P., Dorner T., Olech E., Martin C., et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One 2014, 9:e87379.
17. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
18. Petri M., Stohl W., Chatham W., McCune W.J., Chevrier M., Ryel J., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459.
19. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48:3475-3486.
20. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
21. Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzova D., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.
22. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
23. Dooley M.A., Houssiau F., Aranow C., D'Cruz D.P., Askanase A., Roth D.A., et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013, 22:63-72.
24. Dall'Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150.
25. Ginzler E.M., Wax S., Rajeswaran A., Copt S., Hillson J., Ramos E., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012, 14:R33.
26. Genovese M.C., Kinnman N., de La Bourdonnaye G., Pena Rossi C., Tak P.P. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011, 63:1793-1803.
27. Isenberg D., Gordon C., Licu D., Copt S., Rossi C.P., Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2014, http://dx.doi.org/10.1136/annrheumdis-2013-205067. Epub ahead of print.
28. Alexander T., Sarfert R., Klotsche J., Kuhl A.A., Rubbert-Roth A., Lorenz H.M., et al. The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 2015, 74:1474-1478.
29. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727.
30. Grammer A.C., Slota R., Fischer R., Gur H., Girschick H., Yarboro C., et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520.
31. Huang W., Sinha J., Newman J., Reddy B., Budhai L., Furie R., et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002, 46:1554-1562.
32. Finck B.K., Linsley P.S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
33. Furie R., Nicholls K., Cheng T.T., Houssiau F., Burgos-Vargas R., Chen S.L., et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014, 66:379-389.
34. Merrill J.T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D.J., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:3077-3087.
35. Wofsy D.A.A., Cagnoli P.C., Chatham W.W., et al. Treatment of lupus nephritis with abatacept plus low-dose pulse cyclophosphamide followed by azathioprine (the Euro-Lupus Regimen): twenty-four week data from a double-blind controlled trial. Arthritis Rheum 2013, 65(Suppl 10):884.
36. Wofsy D., Hillson J.L., Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012, 64:3660-3665.
37. Bengtsson A.A., Sturfelt G., Truedsson L., Blomberg J., Alm G., Vallin H., et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000, 9:664-671.
38. Crow M.K., Kirou K.A., Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003, 36:481-490.
39. Aringer M., Houssiau F., Gordon C., Graninger W.B., Voll R.E., Rath E., et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48:1451-1454.
40. Szepietowski J.C., Nilganuwong S., Wozniacka A., Kuhn A., Nyberg F., van Vollenhoven R.F., et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 2013, 65:2661-2671.
41. van Vollenhoven R., Rovin B., Wagner C., Zhou B., Gordon R., Hsu B. A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis. Ann Rheum Dis 2014, 73(Suppl 2):78.
42. Yu C.C., Fornoni A., Weins A., Hakroush S., Maiguel D., Sageshima J., et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013, 369:2416-2423.
43. Dall'Era M., Stone D., Levesque V., Cisternas M., Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken) 2011, 63:351-357.
44. Dall'Era M., Cisternas M., Smilek D., Straub L., Houssiau F., Cervera R., et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis Cohort. Arthritis Rheumatol 2015, 67:1305-1313.